Epstein Secrets

magine' policing." EFTA00150746 Grassley: Senate Would "Probably" Override Trump Veto Of Defense Bill. The Hill (7/7, Carney, 2.98M) reports Sen. Charles Grassley (R-IA) "is warning that Congress would likely override President Trump if he vetoes a mammoth defense policy bill amid the fight over a plan to ren

shown to be effective in clinical trials." CNN (7/7, Cohen, Bonifield, 83.16M) reports on its website that Novavax CEO/President Stanley Erck "said Novavax's vaccine could be on the market by the first quarter of next year." The Hill (7/7, Budryk, 2.98M) reports that "the award will also cover a large-

rnment To Pay $1.6B For Rush Vaccine Development. The CBS Evening NewsVi (7/7, story 3, 1:40, O'Donnell, 4.24M) reported, "Maryland biotech company Novavax is in the hunt for a coronavirus vaccine, and getting a major dose of funding from the government's Operation Warp Speed program." The New York lime

I's investigation into Michael Flynn, two Senate-panel chairmen said Monday." Taylor "authored an op-ed vowing resistance to President Trump." Sens. Charles Grassley (R-IA) and Ron Johnson (R- WI) "cited a newly-declassified May 2017 Justice Department document summarizing the FBI's efforts in its EFTA00137303

ted by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behi

's investigation into Michael Flynn, two Senate-panel chairmen said Monday." Taylor "authored an op-ed vowing resistance to President Trump." Sens. Charles Grassley (R-IA) and Ron Johnson (R-WI) "cited a newly-declassified May 2017 Justice Department document summarizing the FBI's efforts in its Russian collusio

ed by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behin